Vaccine

Abstract

BackgroundInfection with hepatitis A and hepatitis B virus can increase the risk of morbidity and mortality in persons with chronic liver disease (CLD). The Advisory Committee on Immunization Practices recommends hepatitis A (HepA) and hepatitis B (HepB) vaccination for persons with CLD.MethodsData from the 2014 and 2015 National Health Interview Surveys (NHIS), nationally representative, in-person interview surveys of the non-institutionalized US civilian population, were used to assess self-reported HepA ( 651 and 652 doses) and HepB vaccination ( 651 and 653 doses) coverage among adults who reported a chronic or long-term liver condition. Multivariable logistic regression was used to identify factors independently associated with HepA and HepB vaccination among adults with CLD.ResultsOverall, 19.4% and 11.5% of adults aged 6518 years with CLD reported receiving 651 dose and 652 doses of HepA vaccine, respectively, compared with 14.7% and 9.1% of adults without CLD (p<0.05 comparing those with and without CLD, 651dose). Age, education, geographic region, and international travel were associated with receipt of 652 doses HepA vaccine among adults with CLD. Overall, 35.7% and 29.1% of adults with CLD reported receiving 651 dose and 653 doses of HepB vaccine, respectively, compared with 30.2% and 24.7% of adults without CLD (p<0.05 comparing those with and without CLD, 651 dose). Age, education, and receipt of influenza vaccination in the past 12 months were associated with receipt of 653 doses HepB vaccine among adults with CLD. Among adults with CLD and 6510 provider visits, only 13.8% and 35.3% had received 652 doses HepA and 653 doses HepB vaccine, respectively.ConclusionsHepA and HepB vaccination among adults with CLD is suboptimal and missed opportunities to vaccinate occurred. Providers should adhere to recommendations to vaccinate persons with CLD to increase vaccination among this population.CC999999/ImCDC/Intramural CDC HHS/United States2018-04-21T00:00:00Z29395521PMC580559